Apalutamide Study Again Demonstrates the Advantages of Nanoforming Over Traditional Cancer Treatment Formulations
Press Release Nanoform Finland Plc February 29, 2024 08:11 a.m. Finnish time / 07:11 a.m. Swedish time Apalutamide Study Again Demonstrates the Advantages of Nanoforming Over Traditional Cancer Treatment Formulations Helsinki, Finland – February 29, 2024 – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced it had received positive results from its own pre-clinical, in-vivo study of a nanocrystalline-enabled apalutamide oral formulation, which shows potential to enable a much smaller tablet than Erleada[® [1]], a nonsteroidal